leflunomide has been researched along with Disease Models, Animal in 43 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012." | 8.89 | Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. ( O'Doherty, C; Polasek, TM; Rowland, A; Sorich, MJ; Wiese, MD, 2013) |
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 7.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| "Wistar albino type rats were randomly divided into five groups: control, sham, leflunomide, sepsis, and sepsis + leflunomide." | 7.80 | Protective effect of leflunomide against oxidative intestinal injury in a rodent model of sepsis. ( Fadillioglu, E; Karaman, A; Ozturk, E; Samdancı, E; Surucu, M, 2014) |
| "Oral administration of leflunomide effectively suppressed IRBP-induced uveitis in rats." | 7.79 | Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. ( Fang, CB; He, Y; Huang, C; Li, J; Lin, Z; Zhan, SX; Zhou, DX, 2013) |
| " In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity." | 7.78 | Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. ( He, C; Liu, S; Lu, X; Luo, P; Wu, M; Yan, Z; Yu, Y, 2012) |
| "The effects of A771726, the active metabolite of leflunomide, on experimental rat corneal neovascularization (NV) in vivo and on cultured human umbilical vein endothelial cells in vitro were studied." | 7.74 | The active metabolite of leflunomide A771726 inhibits corneal neovascularization. ( Bian, F; Hao, N; Zhang, M, 2008) |
| "The effect of immunomodulator leflunomide on the development of an experimental endometriosis model was assessed by surgically transplanting autologous fragments of endometrial tissue onto the inner surface of the abdominal wall and arterial cascades of the small intestines." | 7.74 | Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. ( Aytan, H; Batioglu, S; Caglar, P; Uygur, D; Zergeroglu, S, 2007) |
| "Leflunomide appeared to cause regression of experimental endometriosis in rats." | 7.73 | Leflunomide--an immunomodulator--induces regression of endometrial explants in a rat model of endometriosis. ( Aytan, H; Batioglu, S; Uygur, D; Zergeroglu, S, 2006) |
| "Angiogenesis plays an important role in bladder cancer (BCa)." | 5.48 | Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer. ( Chu, M; Zhang, C, 2018) |
| "When treated with leflunomide, the neuroblastoma cell lines BE(2)-C, SK-N-DZ, and SK-N-F1 showed dramatic inhibition of DHODH at mRNA and protein levels." | 5.39 | Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. ( Cui, H; Ding, HF; Xiang, Z; Yan, X; Zhu, S, 2013) |
| "Treatment with leflunomide in vivo prevented allergen-induced mast cell degranulation in vitro because the mast cells lacked IgE on their surface." | 5.30 | Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma. ( Eber, E; McMenamin, C; Sly, PD; Uhlig, T, 1998) |
| "Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012." | 4.89 | Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. ( O'Doherty, C; Polasek, TM; Rowland, A; Sorich, MJ; Wiese, MD, 2013) |
| " In the present study, the potential side effects of combination leflunomide and methotrexate (LEF+MTX), a conventional rheumatoid arthritis therapy used in the resolution of liver fibrosis, was investigated." | 3.91 | Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance. ( Guo, R; Ke, S; Lin, M; Su, Z; Zeng, D, 2019) |
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 3.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| "Wistar albino type rats were randomly divided into five groups: control, sham, leflunomide, sepsis, and sepsis + leflunomide." | 3.80 | Protective effect of leflunomide against oxidative intestinal injury in a rodent model of sepsis. ( Fadillioglu, E; Karaman, A; Ozturk, E; Samdancı, E; Surucu, M, 2014) |
| "Oral administration of leflunomide effectively suppressed IRBP-induced uveitis in rats." | 3.79 | Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. ( Fang, CB; He, Y; Huang, C; Li, J; Lin, Z; Zhan, SX; Zhou, DX, 2013) |
| " In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity." | 3.78 | Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. ( He, C; Liu, S; Lu, X; Luo, P; Wu, M; Yan, Z; Yu, Y, 2012) |
| "The changes of plasma dihydrorhodamine 123 oxidation level, the myeloperoxidase activity, and extravasations of Evans blue dye of lung in wild-type mice with or without c-Jun NH2-terminal kinase inhibitor; c-Jun NH2-terminal kinase1 mice and c-Jun NH2-terminal kinase1 mice; and chimeric mice (wild-type --> wild-type, c-Jun NH2-terminal kinase1 --> wild-type) with Pseudomonas aeruginosa-induced peritonitis were determined to evaluate the role of c-Jun NH2-terminal kinase signaling of the hematopoietic cells in peritonitis-induced lung damage." | 3.76 | Peritonitis-induced peroxynitrite and lung damage depends on c-Jun NH2-terminal kinase signaling of hematopoietic cells. ( Chen, LW; Chen, PH; Hsu, CM; Tseng, HT, 2010) |
| "The effects of A771726, the active metabolite of leflunomide, on experimental rat corneal neovascularization (NV) in vivo and on cultured human umbilical vein endothelial cells in vitro were studied." | 3.74 | The active metabolite of leflunomide A771726 inhibits corneal neovascularization. ( Bian, F; Hao, N; Zhang, M, 2008) |
| "The effect of immunomodulator leflunomide on the development of an experimental endometriosis model was assessed by surgically transplanting autologous fragments of endometrial tissue onto the inner surface of the abdominal wall and arterial cascades of the small intestines." | 3.74 | Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. ( Aytan, H; Batioglu, S; Caglar, P; Uygur, D; Zergeroglu, S, 2007) |
| "Leflunomide can decrease the deposit of immunocomplex, down regulate the expression of TGF-beta1, MCP-1 in kidney, diminish local inflammatory reaction, relieve hyperplasia of mesangial matrix, related the process of nephrotic fibrosis, and protect renal function." | 3.74 | [Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model]. ( Liu, X; Lou, TQ; Peng, H; Tang, H; Tang, Y; Wang, C, 2008) |
| "Leflunomide appeared to cause regression of experimental endometriosis in rats." | 3.73 | Leflunomide--an immunomodulator--induces regression of endometrial explants in a rat model of endometriosis. ( Aytan, H; Batioglu, S; Uygur, D; Zergeroglu, S, 2006) |
| " Here, we investigated the efficacy of leflunomide and its mode of action in experimental autoimmune encephalomyelitis (EAE), which is a T helper cell type 1 cell-borne disease model to simulate inflammatory aspects of multiple sclerosis and was induced in Lewis rats by adoptive transfer of myelin basic protein (MBP)-specific T line cells." | 3.72 | Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion. ( Jung, S; Korn, T; Magnus, T; Toyka, K, 2004) |
| "Leflunomide has been shown to be very effective in preventing and curing several autoimmune animal diseases." | 2.38 | Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. ( Bartlett, RR; Bremer, E; Dimitrijevic, M; Germann, T; Küchle, CC; Mattar, T; Rüde, E; Schorlemmer, HU; Thoenes, GH; Zielinski, T, 1991) |
| "Angiogenesis plays an important role in bladder cancer (BCa)." | 1.48 | Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer. ( Chu, M; Zhang, C, 2018) |
| "Oral squamous cell carcinoma (OSCC) is the most prevalent pathological cancer occurring in the head and neck area." | 1.46 | Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma. ( Cui, H; Fu, G; Qiu, Y; Ren, A, 2017) |
| "When treated with leflunomide, the neuroblastoma cell lines BE(2)-C, SK-N-DZ, and SK-N-F1 showed dramatic inhibition of DHODH at mRNA and protein levels." | 1.39 | Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. ( Cui, H; Ding, HF; Xiang, Z; Yan, X; Zhu, S, 2013) |
| "Melanoma is a tumour of transformed melanocytes, which are originally derived from the embryonic neural crest." | 1.37 | DHODH modulates transcriptional elongation in the neural crest and melanoma. ( Burke, CJ; Cech, J; Chen, F; Datta, S; Granter, S; Kaufman, C; Kramer, M; Langdon, E; Lin, CY; Long, HK; Morrison, S; Mosher, J; Neuberg, D; Rahl, PB; Ratanasirintrawoot, S; Tomlinson, ML; Wheeler, GN; White, RM; Young, RA; Zon, LI, 2011) |
| "Leflunomide pretreatment significantly ameliorated pancreatic hemorrhage, edema, and neutrophil infiltration and decreased histopathological score compared with the untreated severe necrotizing pancreatitis group (pathological score [mean +/- SEM]: 6." | 1.36 | Leflunomide: is a new oral agent in treatment of acute pancreatitis? ( Kaptanoglu, B; Kutluana, U; Nart, D; Oruc, N; Ozutemiz, O; Yonetci, N, 2010) |
| "Though cerebral vasospasm is one of the most serious complications of subarachnoid haemorrhage (SAH), its complex pathogenesis is poorly understood and available clinical treatment options are unsatisfactory." | 1.34 | Leflunomide prevents vasospasm secondary to subarachnoid haemorrhage. ( Belen, D; Besalti, O; Bolay, H; Kösemehmetoğlu, K; Simşek, S; Yiğitkanli, K, 2007) |
| "Leflunomide is a new low molecular weight immunosuppressive drug which inhibits the enzymes dehydroorotate-dehydrogenase and protein tyrosine kinase, both of which are important components in the immune response." | 1.30 | The effects of leflunomide and cyclosporin A on rejection of cardiac allografts in the rat. ( Ekberg, H; Hedlund, G; Ostraat, O; Qi, ZQ; Tufveson, G, 1998) |
| "Treatment with leflunomide in vivo prevented allergen-induced mast cell degranulation in vitro because the mast cells lacked IgE on their surface." | 1.30 | Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma. ( Eber, E; McMenamin, C; Sly, PD; Uhlig, T, 1998) |
| "When uridine was added to the cell culture, this molecule's effect on cell proliferation was completely restored, whereas the antibody production was partially restored." | 1.30 | Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. ( Amano, Y; Kitagawa, H; Mizushima, Y; Ogata, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.33) | 18.7374 |
| 1990's | 10 (23.26) | 18.2507 |
| 2000's | 11 (25.58) | 29.6817 |
| 2010's | 20 (46.51) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Morin, F | 1 |
| Kavian, N | 1 |
| Chouzenoux, S | 1 |
| Cerles, O | 1 |
| Nicco, C | 1 |
| Chéreau, C | 1 |
| Batteux, F | 1 |
| Bilger, A | 1 |
| Plowshay, J | 1 |
| Ma, S | 1 |
| Nawandar, D | 1 |
| Barlow, EA | 1 |
| Romero-Masters, JC | 1 |
| Bristol, JA | 1 |
| Li, Z | 1 |
| Tsai, MH | 1 |
| Delecluse, HJ | 1 |
| Kenney, SC | 1 |
| Ren, A | 1 |
| Fu, G | 1 |
| Qiu, Y | 1 |
| Cui, H | 2 |
| Chu, M | 1 |
| Zhang, C | 1 |
| Ma, ZG | 1 |
| Zhang, X | 1 |
| Yuan, YP | 1 |
| Jin, YG | 1 |
| Li, N | 1 |
| Kong, CY | 1 |
| Song, P | 1 |
| Tang, QZ | 1 |
| Lin, M | 1 |
| Guo, R | 1 |
| Su, Z | 1 |
| Ke, S | 1 |
| Zeng, D | 1 |
| Yu, M | 1 |
| Nguyen, ND | 1 |
| Huang, Y | 1 |
| Lin, D | 1 |
| Fujimoto, TN | 1 |
| Molkentine, JM | 1 |
| Deorukhkar, A | 1 |
| Kang, Y | 1 |
| San Lucas, FA | 1 |
| Fernandes, CJ | 1 |
| Koay, EJ | 1 |
| Gupta, S | 1 |
| Ying, H | 1 |
| Koong, AC | 1 |
| Herman, JM | 1 |
| Fleming, JB | 1 |
| Maitra, A | 1 |
| Taniguchi, CM | 1 |
| Fang, CB | 1 |
| Zhou, DX | 1 |
| Zhan, SX | 1 |
| He, Y | 1 |
| Lin, Z | 1 |
| Huang, C | 1 |
| Li, J | 1 |
| Wiese, MD | 1 |
| Rowland, A | 1 |
| Polasek, TM | 1 |
| Sorich, MJ | 1 |
| O'Doherty, C | 1 |
| Zhu, S | 1 |
| Yan, X | 1 |
| Xiang, Z | 1 |
| Ding, HF | 1 |
| Ozturk, E | 2 |
| Surucu, M | 2 |
| Karaman, A | 2 |
| Samdancı, E | 1 |
| Fadillioglu, E | 3 |
| Deng, F | 1 |
| Zhang, P | 1 |
| Feng, J | 1 |
| Wang, L | 1 |
| Demirbilek, S | 1 |
| Begec, Z | 1 |
| Kirimlioglu, H | 2 |
| Ersoy, MO | 1 |
| Zhang, M | 1 |
| Hao, N | 1 |
| Bian, F | 1 |
| Chiba, Y | 1 |
| Nakazawa, S | 1 |
| Todoroki, M | 1 |
| Shinozaki, K | 1 |
| Sakai, H | 1 |
| Misawa, M | 1 |
| Yildiz, Y | 1 |
| Kose, H | 1 |
| Cecen, S | 1 |
| Ergin, K | 1 |
| Demir, EM | 1 |
| Serter, M | 1 |
| Kutluana, U | 1 |
| Oruc, N | 1 |
| Nart, D | 1 |
| Kaptanoglu, B | 1 |
| Yonetci, N | 1 |
| Ozutemiz, O | 1 |
| Tas, E | 1 |
| Karadag, N | 1 |
| Gülsul, C | 1 |
| Demircan, M | 1 |
| Chen, LW | 1 |
| Tseng, HT | 1 |
| Chen, PH | 1 |
| Hsu, CM | 1 |
| Bloudícková, S | 1 |
| Rajnoch, J | 1 |
| Lodererová, A | 1 |
| Honsová, E | 1 |
| Viklický, O | 1 |
| He, C | 1 |
| Lu, X | 1 |
| Yan, Z | 1 |
| Wu, M | 1 |
| Liu, S | 1 |
| Yu, Y | 1 |
| Luo, P | 1 |
| White, RM | 1 |
| Cech, J | 1 |
| Ratanasirintrawoot, S | 1 |
| Lin, CY | 1 |
| Rahl, PB | 1 |
| Burke, CJ | 1 |
| Langdon, E | 1 |
| Tomlinson, ML | 1 |
| Mosher, J | 1 |
| Kaufman, C | 1 |
| Chen, F | 1 |
| Long, HK | 1 |
| Kramer, M | 1 |
| Datta, S | 1 |
| Neuberg, D | 1 |
| Granter, S | 1 |
| Young, RA | 1 |
| Morrison, S | 1 |
| Wheeler, GN | 1 |
| Zon, LI | 1 |
| Korn, T | 1 |
| Magnus, T | 1 |
| Toyka, K | 1 |
| Jung, S | 1 |
| Wei, YH | 1 |
| Li, Y | 1 |
| Qiang, CJ | 1 |
| Davis, IC | 1 |
| Lazarowski, ER | 1 |
| Hickman-Davis, JM | 1 |
| Fortenberry, JA | 1 |
| Chen, FP | 1 |
| Zhao, X | 1 |
| Sorscher, E | 1 |
| Graves, LM | 1 |
| Sullender, WM | 1 |
| Matalon, S | 1 |
| Weigmann, B | 1 |
| Jarman, ER | 1 |
| Sudowe, S | 1 |
| Bros, M | 1 |
| Knop, J | 1 |
| Reske-Kunz, AB | 1 |
| Uygur, D | 2 |
| Aytan, H | 2 |
| Zergeroglu, S | 2 |
| Batioglu, S | 2 |
| Caglar, P | 1 |
| Belen, D | 1 |
| Besalti, O | 1 |
| Yiğitkanli, K | 1 |
| Kösemehmetoğlu, K | 1 |
| Simşek, S | 1 |
| Bolay, H | 1 |
| Tang, Y | 1 |
| Lou, TQ | 1 |
| Wang, C | 1 |
| Peng, H | 1 |
| Liu, X | 1 |
| Tang, H | 1 |
| Bartlett, RR | 4 |
| Anagnostopulos, H | 1 |
| Zielinski, T | 3 |
| Mattar, T | 2 |
| Schleyerbach, R | 1 |
| Brendel, S | 1 |
| Schorlemmer, HU | 2 |
| Ostraat, O | 1 |
| Qi, ZQ | 1 |
| Tufveson, G | 1 |
| Hedlund, G | 1 |
| Ekberg, H | 1 |
| Eber, E | 2 |
| Uhlig, T | 2 |
| McMenamin, C | 2 |
| Sly, PD | 2 |
| Cooper, D | 1 |
| Wildhaber, JH | 1 |
| Yin, D | 1 |
| Ma, LL | 1 |
| Blinder, L | 2 |
| Shen, J | 2 |
| Sankary, H | 2 |
| Williams, JW | 2 |
| Chong, AS | 2 |
| Xiao, F | 1 |
| Liu, W | 1 |
| Huang, W | 1 |
| Foster, P | 1 |
| Jensik, S | 1 |
| McChesney, L | 1 |
| Mital, D | 1 |
| Mizushima, Y | 1 |
| Amano, Y | 1 |
| Kitagawa, H | 1 |
| Ogata, K | 1 |
| Breedveld, FC | 1 |
| Dimitrijevic, M | 1 |
| Germann, T | 1 |
| Rüde, E | 1 |
| Thoenes, GH | 1 |
| Küchle, CC | 1 |
| Bremer, E | 1 |
| Popovic, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS[NCT03464448] | 30 participants (Actual) | Observational | 2018-04-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for leflunomide and Disease Models, Animal
| Article | Year |
|---|---|
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Top | 2013 |
Effects of leflunomide on immune responses and models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Autoimmune Diseases; Cytokines | 1993 |
Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Arthritis, Rheumatoid; Autoimm | 1996 |
Investigational treatments in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; | 1999 |
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.
Topics: Amino Acid Sequence; Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Disease | 1991 |
38 other studies available for leflunomide and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Leflunomide prevents ROS-induced systemic fibrosis in mice.
Topics: Animals; Antirheumatic Agents; Autoantibodies; Bleomycin; Cells, Cultured; Disease Models, Animal; F | 2017 |
Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Line, Transformed; Cell Proliferation; Crotonates; Cyclin E; | 2017 |
Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Pro | 2017 |
Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; En | 2018 |
A77 1726 (leflunomide) blocks and reverses cardiac hypertrophy and fibrosis in mice.
Topics: Animals; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Heart | 2018 |
Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Collagen Type III; Collagen Type IV; Disease M | 2019 |
Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; CRISPR-Cas Systems; Disease Models, Animal; Dynamins; Enzyme | 2019 |
Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.
Topics: Animals; Autoimmune Diseases; Chemokines; Disease Models, Animal; Eye; Female; Gene Expression Regul | 2013 |
Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dihydroorotate Dehydrogenase; Disease Mode | 2013 |
Protective effect of leflunomide against oxidative intestinal injury in a rodent model of sepsis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biomarkers; Catalase; Cecum; Disease | 2014 |
[Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis].
Topics: Animals; Chronic Disease; Disease Models, Animal; Glomerulonephritis; Inflammation; Interleukin-6; I | 2016 |
Does leflunomide attenuate the sepsis-induced acute lung injury?
Topics: Acute Lung Injury; Adjuvants, Immunologic; Animals; Disease Models, Animal; Glutathione; Immunosuppr | 2008 |
The active metabolite of leflunomide A771726 inhibits corneal neovascularization.
Topics: Aniline Compounds; Animals; Cell Nucleus; Cell Proliferation; Corneal Neovascularization; Crotonates | 2008 |
Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchoalveolar Lavage; Cell Line; Disease | 2009 |
Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catalase; Disease Models, Animal; Dose-Response Re | 2010 |
Leflunomide: is a new oral agent in treatment of acute pancreatitis?
Topics: Administration, Oral; Amylases; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Isoxazole | 2010 |
Effect of leflunomide on liver regeneration after partial hepatectomy in rats.
Topics: Adjuvants, Immunologic; Animals; Catalase; Disease Models, Animal; Hepatectomy; Immunosuppressive Ag | 2010 |
Peritonitis-induced peroxynitrite and lung damage depends on c-Jun NH2-terminal kinase signaling of hematopoietic cells.
Topics: Animals; Anthracenes; Blotting, Western; Dimethyl Sulfoxide; Disease Models, Animal; Hematopoiesis; | 2010 |
Leflunomide derivate FK 778 in accelerated renal injury in transgenic rat.
Topics: Alkynes; Animals; Blood Pressure; Disease Models, Animal; Immunosuppressive Agents; Isoxazoles; Kidn | 2010 |
Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice.
Topics: Animals; Antigen-Antibody Complex; Ascites; Cell Proliferation; Disease Models, Animal; Female; Graf | 2012 |
DHODH modulates transcriptional elongation in the neural crest and melanoma.
Topics: Amino Acid Substitution; Animals; Animals, Genetically Modified; Cell Differentiation; Cell Line, Tu | 2011 |
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
Topics: Adoptive Transfer; Animals; Animals, Newborn; Antigens, CD; B7-2 Antigen; Cells, Cultured; Chemotaxi | 2004 |
Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats.
Topics: Animals; Arthritis, Experimental; Body Weight; Cell Proliferation; China; Disease Models, Animal; Do | 2004 |
Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus.
Topics: Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Disease Progression | 2006 |
Induction of regulatory T cells by leflunomide in a murine model of contact allergen sensitivity.
Topics: Allergens; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Dermatitis, A | 2006 |
Leflunomide--an immunomodulator--induces regression of endometrial explants in a rat model of endometriosis.
Topics: Animals; Disease Models, Animal; Endometriosis; Endometrium; Female; Immunologic Factors; Isoxazoles | 2006 |
Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model.
Topics: Animals; Disease Models, Animal; Endometriosis; Female; Immunologic Factors; Isoxazoles; Leflunomide | 2007 |
Leflunomide prevents vasospasm secondary to subarachnoid haemorrhage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Basilar Artery; Disease Models, Animal; Fibromuscu | 2007 |
[Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model].
Topics: Animals; Chemokine CCL2; Disease Models, Animal; Fibrosis; Glomerulonephritis, IGA; Isoxazoles; Kidn | 2008 |
The effects of leflunomide and cyclosporin A on rejection of cardiac allografts in the rat.
Topics: Animals; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gra | 1998 |
Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma.
Topics: Allergens; Animals; Asthma; Bronchial Provocation Tests; Cell Degranulation; Dimercaprol; Disease Mo | 1998 |
Effects of long-term oral treatment with leflunomide on allergic sensitization, lymphocyte activation, and airway inflammation in a rat model of asthma.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Animals; Anti-Inflammatory Agents; An | 1998 |
Induction of species-specific host accommodation in the hamster-to-rat xenotransplantation model.
Topics: Acute Disease; Animals; Cricetinae; Cyclosporine; Disease Models, Animal; Drug Combinations; Graft R | 1998 |
Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation.
Topics: Animals; Chronic Disease; Cricetinae; Cyclosporine; Disease Models, Animal; Graft Rejection; Heart T | 1998 |
Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.
Topics: Administration, Oral; Aniline Compounds; Animals; Antibody Specificity; Crotonates; Disease Models, | 1999 |
The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery.
Topics: Animals; Cyclophosphamide; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Graft vs Ho | 1987 |